Cancer Institute Hospital of JFCR ( Site 3404)

Koto, Tokyo 135-8550

2 studies enrolling now · 2 studies all time

What they study most

Non-small Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — Recruiting now
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) — Recruiting now